JP2016505023A - 肺の状態の処置 - Google Patents

肺の状態の処置 Download PDF

Info

Publication number
JP2016505023A
JP2016505023A JP2015552904A JP2015552904A JP2016505023A JP 2016505023 A JP2016505023 A JP 2016505023A JP 2015552904 A JP2015552904 A JP 2015552904A JP 2015552904 A JP2015552904 A JP 2015552904A JP 2016505023 A JP2016505023 A JP 2016505023A
Authority
JP
Japan
Prior art keywords
composition
leucine
methylxanthine
theophylline
resveratrol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015552904A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505023A5 (enExample
Inventor
マイケル ジメル，
マイケル ジメル，
アンチェ ブルックバウアー，
アンチェ ブルックバウアー，
ブルック バゲット，
ブルック バゲット，
Original Assignee
ニューサート サイエンシーズ， インコーポレイテッド
ニューサート サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューサート サイエンシーズ， インコーポレイテッド, ニューサート サイエンシーズ， インコーポレイテッド filed Critical ニューサート サイエンシーズ， インコーポレイテッド
Publication of JP2016505023A publication Critical patent/JP2016505023A/ja
Publication of JP2016505023A5 publication Critical patent/JP2016505023A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2015552904A 2013-01-15 2014-01-14 肺の状態の処置 Pending JP2016505023A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752909P 2013-01-15 2013-01-15
US61/752,909 2013-01-15
PCT/US2014/011531 WO2014113404A1 (en) 2013-01-15 2014-01-14 Treating pulmonary conditions

Publications (2)

Publication Number Publication Date
JP2016505023A true JP2016505023A (ja) 2016-02-18
JP2016505023A5 JP2016505023A5 (enExample) 2017-02-16

Family

ID=51210014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015552904A Pending JP2016505023A (ja) 2013-01-15 2014-01-14 肺の状態の処置

Country Status (6)

Country Link
US (3) US20150359771A1 (enExample)
EP (1) EP2945616B1 (enExample)
JP (1) JP2016505023A (enExample)
CN (1) CN105101958B (enExample)
AU (1) AU2014207707B2 (enExample)
WO (1) WO2014113404A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012284267B2 (en) 2011-07-15 2017-06-29 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
JP6469015B2 (ja) 2012-11-13 2019-02-13 ニューサート サイエンシーズ， インコーポレイテッド エネルギー代謝を増大させるための組成物および方法
EP2945616B1 (en) 2013-01-15 2018-11-28 NuSirt Sciences, Inc. Treating pulmonary conditions
WO2014149280A1 (en) * 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators
CA2902879C (en) 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
WO2015006465A1 (en) * 2013-07-10 2015-01-15 Ahkeo Ventures LLC Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same
CA2939833A1 (en) 2014-02-27 2015-09-03 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
CN107998110A (zh) * 2018-01-11 2018-05-08 上海市普陀区中心医院 白藜芦醇用于制备治疗或缓解慢性气道炎症性疾病用药物的用途
US10830778B2 (en) * 2018-05-24 2020-11-10 C Technologies, Inc. Slope spectroscopy standards
US10568352B1 (en) 2018-10-25 2020-02-25 Wiser Concepts, LLC Nutritional compositions and methods of treatment therewith
US11437483B2 (en) 2020-03-05 2022-09-06 Intel Corporation Gate-all-around integrated circuit structures having dual nanoribbon channel structures

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006049286A1 (ja) * 2004-11-02 2006-05-11 Ajinomoto Co., Inc. アレルギー性疾患予防・治療剤
JP2007530542A (ja) * 2004-03-26 2007-11-01 アボット・ラボラトリーズ Ｈｍｂ組成物及びその使用
WO2011146031A1 (en) * 2010-05-18 2011-11-24 Bilgic Mahmut Pharmaceutical composition comprising n- acetylcysteine and a xanthine

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
IE58246B1 (en) 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB8919131D0 (en) 1989-08-23 1989-10-04 Riker Laboratories Inc Inhaler
EP0511587A1 (en) * 1991-04-26 1992-11-04 Takeda Chemical Industries, Ltd. Slimming composition
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US20010051654A1 (en) * 1997-09-25 2001-12-13 Elliott Peter J. Treatment of inflammatory and autoimmune diseases
JP3611456B2 (ja) 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
AU765909C (en) 1998-12-17 2004-09-23 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
EP1461101A4 (en) * 2001-12-07 2005-02-09 Glaxo Group Ltd DOSAGE VALVE, PHARMACEUTICAL AGENT AEROSOL-DOSER, AND METHODS THEREOF
AU2003231788B2 (en) 2002-05-17 2008-09-11 Duke University Method for treating obesity
JP4485945B2 (ja) 2002-06-26 2010-06-23 インターシア セラピューティクス，インコーポレイティド 浸透圧デリバリーシステムの最小服従型で、容積効率型ピストン
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US20060173079A1 (en) * 2003-01-10 2006-08-03 Universiteit Van Maastricht Compositions and methods for improving the condition of patients suffering from copd and other diseases
WO2005065726A1 (en) * 2003-12-30 2005-07-21 Dr. Reddy's Laboratories Ltd. Pharmaceutical composition
WO2006009769A1 (en) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
EP1845994B1 (en) * 2005-02-11 2009-01-21 Argenta Discovery Limited Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases
EA013474B1 (ru) 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
KR20080108487A (ko) 2006-02-28 2008-12-15 트르스티스 오브 보스톤 유니버시티 대사 조절인자 및 그의 용도
DE102006016903A1 (de) 2006-04-11 2007-10-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalator
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
WO2010086746A2 (en) * 2009-01-28 2010-08-05 Life Science Nutrition As Compositions and methods of treating viral infections
US20110064720A1 (en) * 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
US8173181B2 (en) * 2009-11-09 2012-05-08 Bio-Engineered Supplements & Nutrition, Inc. Method and composition for improved anabolism
AU2012284267B2 (en) * 2011-07-15 2017-06-29 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
EP2945616B1 (en) 2013-01-15 2018-11-28 NuSirt Sciences, Inc. Treating pulmonary conditions
WO2014149280A1 (en) * 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530542A (ja) * 2004-03-26 2007-11-01 アボット・ラボラトリーズ Ｈｍｂ組成物及びその使用
WO2006049286A1 (ja) * 2004-11-02 2006-05-11 Ajinomoto Co., Inc. アレルギー性疾患予防・治療剤
WO2011146031A1 (en) * 2010-05-18 2011-11-24 Bilgic Mahmut Pharmaceutical composition comprising n- acetylcysteine and a xanthine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RESPIROLOGY, 2006, VOL. 11, NO. 5, P. 603-610, JPN6017033348, ISSN: 0003746269 *

Also Published As

Publication number Publication date
US9737501B2 (en) 2017-08-22
EP2945616B1 (en) 2018-11-28
CN105101958A (zh) 2015-11-25
US20170368012A1 (en) 2017-12-28
HK1217169A1 (zh) 2016-12-30
AU2014207707B2 (en) 2018-11-01
AU2014207707A1 (en) 2015-08-13
US10039733B2 (en) 2018-08-07
WO2014113404A1 (en) 2014-07-24
US20150018375A1 (en) 2015-01-15
US20150359771A1 (en) 2015-12-17
CN105101958B (zh) 2019-05-17
EP2945616A4 (en) 2016-06-22
EP2945616A1 (en) 2015-11-25

Similar Documents

Publication Publication Date Title
US10039733B2 (en) Compositions, method, and kits for treating pulmonary conditions
US9895357B2 (en) Compositions, methods and kits for reducing lipid levels
JP6469015B2 (ja) エネルギー代謝を増大させるための組成物および方法
US10344002B2 (en) Compositions and methods for treating metabolic disorders
US20180235917A1 (en) Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
US20220409647A1 (en) Compositions, methods and kits for altering adipocytes
HK1217169B (en) Treating pulmonary conditions
HK1212594B (en) Pde5 inhibitors and leucine or a leucine metabolite for use in the treatment of diabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181025